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Introduction
In sarcoidosis, a disseminated granulomatous disease of unknown origin, practically every organ can w x be involved 1 . Depending on the organs involved and the severity of granulomatous inflammation, symptoms can vary considerably. Besides respiratory symptoms such as coughing and dyspnea on exer-tion, patients often suffer from systemic symptoms w x such as fever, weight loss, and fatigue 2,3 .
In the follow-up of sarcoidosis patients, routine tests to assess disease activity include clinical investigation, chest radiography, and lung function testing w x Ž . 4 . Serum angiotensin converting enzyme sACE , gallium-67 scanning, high resolution computed tomography, and bronchoalveolar lavage parameters may also be useful as indicators of disease activity w x 4 , although they do not necessarily reflect wellbeing of the patient. For example, even if pulmonary 0300-2977r98r$ -see frontmatter q 1998 Elsevier Science B.V. All rights reserved.
Ž . PII S 0 3 0 0 -2 9 7 7 9 8 0 0 0 5 8 -8 ( ) function tests, sACE, and radiographic abnormalities return to normal or show only small impairment, nonspecific symptoms, such as fatigue and reduced exercise capacity may persist.
In other chronic respiratory disorders such as Ž . chronic obstructive pulmonary disease COPD the Ž . correlation of quality of life QOL and physiological measures of disease severity such as forced Ž . expiratory volume in one second FEV have been 1 w x w x found to be either weak [5] [6] [7] [8] or not existent 9 , although respiratory symptoms such as wheezing, dyspnea, and subjective severity of breathing probw x lems were more strongly related to QOL 7, 10 . In a previous study of 64 sarcoidosis patients, we also found that QOL was not associated with pulmonary w x function tests and sACE 11 . The presence of sympw x toms, however, influenced QOL considerably 12 .
The number and severity of symptoms may therefore provide more accurate information on the degree of impairment and the well-being of patients with sarcoidosis than the routinely performed physiological measures of disease activity and severity.
Other epidemiological studies have shown that there are considerable differences between countries, not only in the prevalence of sarcoidosis but also in w x the clinical presentation 13 . For the Netherlands, no extensive epidemiological data exist on the clinical presentation of sarcoidosis. Since the symptoms of sarcoidosis vary considerably, it is essential that pulmonary physicians and other physicians such as general practitioners, internists, and rheumatologists are aware of the possible forms of presentation of this disorder.
Therefore, the aim of the present study was to make an extensive inventory of sarcoidosis-related symptoms in order to gain more information on the presentation of this disorder. Data on family history, duration of the disease, diagnostic procedures, and treatment were also analyzed.
Methods

Patients
All members of the Dutch Sarcoidosis Society Ž . n s 1975 were sent the questionnaire by mail together with a letter from the Dutch Sarcoidosis Society asking patient members to participate in a study on the clinical presentation of sarcoidosis. Of the 1975 members, 1755 members were sarcoidosis pa-Ž . tients. Of these, 1093 sarcoidosis patients 62.3% Ž . responded and 1026 58.5% completed the questionnaire. The remaining 67 persons gave a number of reasons why they did not wish to participate in the Ž . Ž . Ž . Ž . study; i too many questions 14 , ii no time 10 , Ž .
Ž . Ž . iii no symptoms 9 , and iv the diagnosis was made too long ago. Eight persons returned the questionnaire without giving a reason for not filling it in.
Questionnaire
The questionnaire consisted of forty-three items including questions concerning socio-demographic data and medical data such as medical history, family history, duration of disease, diagnostic procedures, treatment, symptoms at onset of the disease and current symptoms. Most of the questions were multiple choice, sometimes giving the possibility to tick more than one answer. A number of questions were open-ended, allowing patients to give information concerning their personal situation. The questionnaire was not standardized. It was pre-tested in a subpopulation of ten sarcoidosis patients.
Statistical analysis
The occurrence of reported symptoms, diagnostic procedures, treatment, and family history were analyzed by frequencies. Data are expressed as absolute numbers, in percentages, and, if appropriate, in mean " SD. In order to detect statistically significant differences, Chi-square tests, Pearson tests, Spearman tests, log-linear analyses and Student's t-tests were used. Probability values smaller than 0.01 were considered to be statistically significant. All analyses were performed using the Statistical Package for Ž . Social Science SPSS .
Results
Characteristics of the study population are summarized in Table 1 . Men and women differed significantly with respect to age. Twenty-six percent of the women were older than 45 years at diagnosis, com- The time interval between the onset of symptoms and the diagnosis was less than three months in 25.5% of cases, three to six months in 17.6% of cases, six to twelve months in 11.6% of cases, and more than one year in 24.5% of cases. This information was missing in 20.8% of cases. A correlation was found between age and time interval between Ž onset of symptoms and diagnosis Pearson's correla-. tion coefficient 0.15, p -0.001 , older patients were diagnosed later.
Ž . In the course of their disease 565 patients 55.1% were treated with systemic corticosteroids, 322 Ž . 31.4% with inhaled corticosteroids, and 323 Ž .
31.5% with nonsteroidal anti-inflammatory drugs.
No data were available with respect to doses andror duration of treatment.
Familial sarcoidosis was reported by 170 patients Ž . Ž . 16.5% . In 106 of these cases 62% a first-degree Ž relative was affected in 47 cases brotherrsister, in 28 cases the mother, in 20 cases the father, and in 11 . cases a child . In 75 cases second-degree relatives suffered from sarcoidosis and in 14 cases two or three relatives were affected by sarcoidosis.
A positive family history with respect to Crohn's Ž . disease was reported by 66 patients 6.4% . In 50 of Ž . these cases 75.7% first-degree family members Ž . were affected. Four patients 0.4% of this study population suffered from both sarcoidosis and Crohn's disease. Table 2 summarizes the symptoms reported by the patients at onset of the disease and at the time of the study. The most frequent symptom at presentation of the sarcoidosis as well as at the time of the study was fatigue. No correlation was found between the symptom fatigue and age. Other frequently reported symptoms were coughing, arthralgia, reduced exercise capacity, muscle pain, and dyspnea. Heart-re- Table 2 The most common symptoms related to sarcoidosis at the time of Ž . diagnosis as well as at the time of this study ns1026
Symptom
At time of diagnosis At time of study n % n % At the onset of the disease only 8.7% of patients suffered from just one symptom, 13.8% suffered from two symptoms, 16.4% from three symptoms, and 12.5% from four symptoms. These percentages did not change significantly over the course of the disease. Correlations were found between the duration of the disease and the symptoms muscle pain Ž . Ž . r s 0.14, p -0.01 , arthralgia r s 0.11, p -0.01 , Ž . heart problems r s 0.14, p -0.001 , skin lesions, Ž . e.g., erythema nodosum r s 0.12, p -0.001 , vi-Ž . sual impairment r s 0.10, p -0.01 , dry mouth Ž . r s 0.10, p -0.01 and reduced exercise capacity Ž . r s 0.09, p -0.01 , respectively. wŽ . x HR CT of the chest was performed, compared with only 30.8% of those diagnosed more than ten Ž . years ago r sy0.18, p -0.001 . Bronchoalveolar Ž . lavage BAL was performed in 32% of the patients diagnosed within the previous four years and in 17% of those who were diagnosed more than ten years Ž . ago r sy0.15, p -0.001 . Of the patients who had suffered from the disease two to eight years, 12.5% had undergone mediastinoscopy, compared with 26.5% of those who were diagnosed more than Ž . ten years ago r s 0.12, p -0.001 . In patients who were diagnosed within the last two years, thoracoscopy was performed in 17.9%, compared with 32.5% of those diagnosed more than ten years ago Ž . r s 0.11, p -0.05 .
Sarcoidosis was the first diagnosis in 57% of the patients. Others were first diagnosed as suffering Ž . from tuberculosis 4.8% and rheumatoid arthritis Ž . 5.1% . In 3.1% of cases a psychological cause was first considered responsible for the reported symp-Ž . toms. In the remaining cases "30% a large range of disorders was first diagnosed, such as bronchus carcinoma, non-Hodgkin lymphoma, diabetes mellitus, hypertension, and pathology of the oesophagus. Of these diagnoses, bronchus carcinoma was the Ž . most frequently reported 2% , the others consisted of a large number of different, isolated diagnoses.
Seventy-five percent of this study population indicated that they regularly visited a chest physician Ž . andror other physicians such as the internist 24.3% , 
Discussion
In this study, the symptoms, diagnostic procedures, treatment, and course of disease were evaluated in a large number of sarcoidosis patients.
This survey of members of the Dutch Sarcoidosis Society showed that persistent fatigue was found to be the most common symptom. Remarkably, fatigue was reported more frequently than respiratory symptoms or any other symptom, in contrast with the results of a recent study comparing the clinical picw x ture of sarcoidosis in Finland and Japan 14 . In Finland the main presenting symptoms were cough-Ž . Ž . ing 33% and in Japan eye symptoms 41% , whereas fatigue was reported in 21% of patients in w x Finland and none in Japan 14 . In our recent study of 64 sarcoidosis patients in the Netherlands, 58% appeared to have actual symptoms. Of this sub-group 80% reported fatigue at the time of diagnosis and 77% still suffered from it at the time of the study w x 12 . In the present study the patients were allowed to report more than one symptom which was present at the onset of the disease and led to medical examination and the correct diagnosis. Moreover, in about half of the patients of the FinishrJapanese study the disease was detected by mass chest radiograph surveys. In the Netherlands no mass chest radiograph surveys are performed, and this may account for the differences between the sarcoidosis population in the Netherlands and these countries.
Sarcoidosis is a disorder that affects the relatively young. The peak incidence for men and women w x occurs between 20 and 40 years 15 . In agreement with this, in our patient group the mean age was 36 years at the onset of the disease. At this age, persistent fatigue and reduced exercise capacity can be expected to interfere severely not only with patients' daily activities but also with their working life.
Although fatigue is a common symptom of many w x chronic diseases 3 , neither the frequency nor the physiological basis of this symptom in sarcoidosis has been studied. Fatigue can be assessed by appropriate QOL instruments such as the World Health Organization Quality of Life assessment instrument Ž .w x WHOQOL-100 16 , or special fatigue measures such as the Profile of Fatigue-Related Symptoms Ž
. w x PFRS 17 , designed for the chronic fatigue syn-Ž . drome CFS . However, data obtained by means of a questionnaire have to be regarded as subjective. If fatigue remains the main symptom, it may be difficult to demonstrate that the patient's impairment is due to sarcoidosis, e.g., for insurance purposes or questions of patients' work capability. Therefore, the physiological basis of fatigue in sarcoidosis needs to be studied and markers must be found in order to assess this symptom more objectively. Recently, we found a relationship between the level of acute phase response proteins and fatigue in sarcoidosis patients w x 18 .
A number of other persistent physical symptoms such as reduced exercise capacity, arthralgia, weakness, starting problems, and muscle pain were reported. The question then arises as to whether these could be expression of muscle involvement. This would be remarkable, considering that symptomatic muscle involvement in sarcoidosis is estimated to w x occur in only 1.4-2.3% of cases 19 . Asymptomatic muscle involvement, however, has been reported in w x 50-80% of cases 20 . In a previous study we showed that reduced respiratory muscle endurance time was related to impaired mobility in a group of sarcoidosis patients, although, no such relationship was found w x with peripheral muscle strength 11 .
Although in this study the patients reported mainly physical symptoms, almost a third of patients also suffered from psycho-social problems such as feeling ( )depressed, tension and strain at the onset of the disease. These problems improved only slightly over time. The latter symptoms were attributed to sarcoidosis by the patients themselves. Previously, we demonstrated that QOL factors were associated with w x depressive symptoms in sarcoidosis 12 . Thus sarcoidosis patients may benefit from psycho-social support and learning different coping strategies as well as attention to the somatic aspects of the disease w x 12 . Further intervention research is needed here, however.
In this study population, 46% had suffered from sarcoidosis for more than eight years. This group reported symptoms such as arthralgia and muscle pain as well as reduced exercise capacity more frequently than patients who were diagnosed less than six years ago. Surprisingly, the same tendency was found for skin lesions such as erythema nodosum. These findings suggest that such persistent symptoms not only impair health status and quality of life of patients with a chronic course of sarcoidosis, but also represent a large demand on health facilities. This demand may mean that the patients make frequent visits to various physicians and require prolonged medication. This may also have economical implications. However, for this patient group no data are available on frequency of visits to the various physicians. Duration of the disease was related only moderately to the number of physicians visited on a regular basis.
Sarcoidosis is thought to occur more frequently in w x women than in men 21 . The study population of Pietinalho and Ohmichi consisted of 59% and 55% w x women in Finland and in Japan, respectively 14 . A recent epidemiological study from Spain, where sarcoidosis is a rare disorder, reported 85% women in w x their study population 22 . In our study 63% of the study population were women.
In a study in the USA, familial sarcoidosis was estimated to occur in 5% of cases among Caucasians w x and in 19% among African Americans 23 . In the present patient group the percentage of familial sar-Ž . coidosis was much higher 16.5% than expected, since only 0.5% of patients were of African descent. In a study of the members of the German sarcoidosis patient organization, a familial sarcoidosis was found w x in 7.5% of cases 24 . In the clinical practice, however, familial sarcoidosis is seen only occasionally and large-scale epidemiological studies are needed to identify 'sarcoidosis families' and undertake the necessary genetic research.
Both sarcoidosis and Crohn's disease are disorders of unknown origin and are characterized by granulomatous inflammation. As the histological characteristics of sarcoidosis and Crohn's disease are similar, a pathogenic relationship has been suggested w x 25 . In one family Gronhagen-Riska et al. found an w x accumulation of both 26 . Cases have also been described, in which patients met the criteria for both, w x Crohn's disease and sarcoidosis 25 . In our study population only four patients reported suffering from both diseases.
In this present study sarcoidosis was the initial diagnosis in only 57% of cases, suggesting that the diagnosis of the disease can be difficult. Other first diagnoses included a wide range of somatic disorders. Also psychological problems were considered to be the cause of the symptoms in a number of patients. Furthermore, only about 25% of the patients were correctly diagnosed within the first three months after the onset of symptoms and in another 25% it took more than one year. A relationship was found with the age of the patients; older people experienced longer delay.
Among the diagnostic procedures used computed Ž . tomography appeared relatively little used 38% , Ž . although especially its high resolution form HRCT is much more sensitive than plain radiographs and can demonstrate early fibrosis and distortion of the w x lung parenchyma 4,27 . Also, bronchoalveolar Ž . lavage BAL was relatively little used, considering w x its importance in the diagnosis of sarcoidosis 28 . Lung biopsies obtained by thoracoscopy and mediastinoscopy were performed relatively often, even though these tests are much more invasive. However, when the use of these tests was correlated with the duration of the disease, we found that in patients Ž . with a shorter time since diagnosis, HR CT and BAL were performed more often and mediastinoscopy and thoracoscopy less often than in those diagnosed more than eight years ago. This reflects recent shifts in management strategies resulting from the development of new diagnostic techniques. The Ž . use of BAL together with HR CT obviates the need for more invasive diagnostic procedures such as thoracoscopy and mediastinoscopy in sarcoidosis.
( )There are several limitations to the present study. Since the data were collected by means of questionnaires completed only by the patients themselves, medical data from their physicians with respect to severity and stage of the disease are lacking. In this patient population it appears that a large number of tests were performed to obtain histological evidence of granulomatous inflammation.
Corticosteroids are regarded as the most effective treatment options for severe symptoms or involvement of eyes, central nervous system or the heart w x 21 . For pulmonary sarcoidosis, objective evidence of deterioration in pulmonary functions has been suggested as an indication of the need for supportive w x treatment 29 . Recently, small long-term advantages from prolonged treatment with systemic corticosteroids were found for patients with pulmonary sarw x coidosis and persistent radiographic shadowing 30 . In contrast, two other studies have found that the rate of relapse was higher for patients treated with cortiw x costeroids than for untreated patients 31,32 . In the present study, 55.1% of patients have received systemic corticosteroids, this is within the range of 30% w x to 100% reported in various other studies 13 . In the present study no relationship was found between the number and kind of symptoms and treatment with corticosteroids. Duration of disease and age, however, were found to be related to treatment with systemic corticosteroids. Inhaled corticosteroids had been used at some time in the course of the disease by 31% of patients, even though these are generally not recommended for the treatment of sarcoidosis w x 33 . However, bronchial hyperresponsiveness is assumed in about 30% of patients with sarcoidosis w x 34 , and this may explain the positive effect of w x inhaled corticosteroids on respiratory symptoms 35 . Moreover, 31% of patients received non steroidal Ž . anti-inflammatory drugs NSAIDs . NSAIDs are w x sometimes used to treat minimal disease 36 , they may not only help to relieve arthralgia and muscle pain but also have an anti-inflammatory effect in sarcoidosis.
In conclusion, the results of this study within a sarcoidosis patient population in the Netherlands indicated that patients present a wide range of physical symptoms, the most common being persistent fatigue. A considerable number of patients suffered from depressive feelings, tension, and strain, many of which persisted over time. No relationship was found between the reported symptoms and treatment with systemic corticosteroids. As the symptom fatigue is difficult to assess objectively, the physiological basis of fatigue in sarcoidosis has to be studied and markers are needed for its accurate assessment. Due to the broad range of possible symptoms, patients with sarcoidosis may consult the family doctor, pulmonologist or any other physician. Therefore, physicians in general should be aware of the many possible presentations of this disorder. Large-scale prospective studies are needed to gain more insight into sarcoidosis, which may be facilitated by a data base, since sarcoidosis remains a relatively rare disorder. In addition, the quality of life and health status should form part of the monitoring of this patient group.
